New Options For Japan As More COVID-19 Vaccines Finally Approved
Nods For Moderna, AstraZeneca
Japan has granted emergency approvals to two more vaccines for COVID-19, both from multinational developers, as it finally expands a so far very limited armory against the pandemic.
You may also be interested in...
India has waived the need for local clinical trials for COVID-19 vaccines already approved in certain other countries, while the WHO has added a Chinese vaccine to its emergency use list. Meanwhile, South Korea issues new guidance for local vaccine trials and Japan gives more money to COVAX.
Moderna's mRNA-1273 vaccine prevented significant illness after two doses in all patients in the TeenCOVE trial, ages 12-18. The company will submit the data to global regulators in June. Meanwhile, J&J has applied for the Japanese approval of its vaccine, Moderna progresses plans in Korea, and India plans to ramp up vaccine supplies.
In this week's podcast version of Five Must-Know Things: Genmab confident in CD20xCD3 battle; Alzheimer’s disappointment for Roche; Japan speed bump for Shionogi’s oral COVID antiviral; pharma’s view of psychedelics; and a roundup of key BIO sessions.